ZA201405400B - Synthetic apelin mimetics for the treatment of heart failure - Google Patents
Synthetic apelin mimetics for the treatment of heart failureInfo
- Publication number
- ZA201405400B ZA201405400B ZA2014/05400A ZA201405400A ZA201405400B ZA 201405400 B ZA201405400 B ZA 201405400B ZA 2014/05400 A ZA2014/05400 A ZA 2014/05400A ZA 201405400 A ZA201405400 A ZA 201405400A ZA 201405400 B ZA201405400 B ZA 201405400B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- heart failure
- synthetic apelin
- mimetics
- apelin mimetics
- Prior art date
Links
- 102000018746 Apelin Human genes 0.000 title 1
- 108010052412 Apelin Proteins 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0066—Blowers or centrifugal pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591557P | 2012-01-27 | 2012-01-27 | |
| US201261717760P | 2012-10-24 | 2012-10-24 | |
| US201261731697P | 2012-11-30 | 2012-11-30 | |
| PCT/IB2013/050666 WO2013111110A2 (en) | 2012-01-27 | 2013-01-25 | Synthetic apelin mimetics for the treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201405400B true ZA201405400B (en) | 2016-08-31 |
Family
ID=47997598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/05400A ZA201405400B (en) | 2012-01-27 | 2014-07-22 | Synthetic apelin mimetics for the treatment of heart failure |
Country Status (42)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| US8921307B2 (en) * | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
| UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| AU2013350802B2 (en) | 2012-11-30 | 2016-07-14 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| EP3907237A1 (en) * | 2012-12-20 | 2021-11-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| EA201591700A1 (ru) * | 2013-03-14 | 2015-12-30 | Ридженерон Фармасьютикалз, Инк. | Гибридные белки апелина и их применение |
| EP3024847A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Disulfide cyclic polypeptides for the treatment of heart failure |
| WO2015013169A2 (en) * | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| WO2015013165A1 (en) * | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic apelin derivatives for the treatment of heart failure |
| EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| CA2931299C (en) | 2013-11-20 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
| ES2729643T3 (es) * | 2013-11-26 | 2019-11-05 | Novartis Ag | Métodos para la conjugación de oxima con polipéptidos modificados con cetona |
| WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
| DK3122764T3 (en) * | 2014-03-25 | 2019-04-15 | Lanthiopep Bv | CYCLIC APELINE ANALOGS |
| GB201407532D0 (en) | 2014-04-29 | 2014-06-11 | Univ Ulster | Apelin analogues |
| JP6721572B2 (ja) | 2014-05-23 | 2020-07-15 | ノバルティス アーゲー | ジスルフィド含有タンパク質からコンジュゲートを作製するための方法 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN106573955B (zh) | 2014-06-23 | 2021-02-26 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| EP3273981B1 (en) * | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| MA42145B1 (fr) | 2015-05-20 | 2020-05-29 | Amgen Inc | Triazoles agonistes du récepteur apj |
| WO2017140684A2 (en) | 2016-02-15 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| CN110072531A (zh) | 2016-10-19 | 2019-07-30 | 阿维夫公司 | 用于治疗心血管相关疾病的爱帕琳的新型聚乙二醇化的脂质体制剂 |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| US12269847B2 (en) | 2018-08-16 | 2025-04-08 | Donaldson Company, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
| KR20210102887A (ko) | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| EP4107268A4 (en) | 2020-02-19 | 2024-03-27 | Donaldson Company, Inc. | PURIFICATION MATRICES COMPRISING VAA-BINDING POLYPEPTIDES AND METHODS OF USE THEREOF |
| US12692483B2 (en) | 2020-02-19 | 2026-07-28 | Donaldson Company, Inc. | Protein-based purification matrices and methods of using the same |
| CN112007027B (zh) * | 2020-09-14 | 2022-07-15 | 长春金赛药业有限责任公司 | 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用 |
| GB202016149D0 (en) * | 2020-10-12 | 2020-11-25 | Heptares Therapeutics Ltd | Cyclic apelin receptor agonists |
| CN119101143A (zh) * | 2023-05-31 | 2024-12-10 | 浙江大学 | 一种G蛋白偏向的apelin-13多肽突变体及应用 |
| WO2026007693A1 (zh) * | 2024-07-05 | 2026-01-08 | 浙江大学 | Apelin-13多肽突变体 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2118372T3 (es) | 1992-11-17 | 1998-09-16 | Icos Corp | Nuevos receptores siete transmembrana v28. |
| US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| CN1283228A (zh) | 1997-12-24 | 2001-02-07 | 武田药品工业株式会社 | 多肽、其生产方法及应用 |
| AU5759399A (en) | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
| ATE440857T1 (de) | 1998-10-05 | 2009-09-15 | Takeda Pharmaceutical | Verfahren zum eliminieren von n-terminalem methionin |
| US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
| US7635751B2 (en) | 2000-03-23 | 2009-12-22 | Takada Pharmaceutical Company Limited | Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof |
| WO2001090123A2 (en) | 2000-05-23 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the agtrl1 gene |
| JP3935487B2 (ja) | 2001-07-16 | 2007-06-20 | フーベルト・ケスター | 捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法 |
| WO2003063892A1 (en) | 2002-01-29 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Use of apelin |
| DE602004027798D1 (de) | 2003-03-12 | 2010-08-05 | Univ Arizona State | Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen |
| US20050152836A1 (en) | 2003-05-22 | 2005-07-14 | Euan Ashley | Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
| US7947280B2 (en) | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
| EP1520861A1 (en) | 2003-09-11 | 2005-04-06 | Aventis Pharma Deutschland GmbH | Test system for the identification of APJ receptor ligands |
| WO2005106493A1 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj) |
| AU2005265164A1 (en) | 2004-06-17 | 2006-01-26 | Musc Foundation For Research Development | Non-natural amino acids |
| US20060045880A1 (en) | 2004-08-23 | 2006-03-02 | Krieg Paul A | Methods for modulating angiogenesis and apoptosis with apelin compositions |
| JP2008013436A (ja) | 2004-10-14 | 2008-01-24 | Kanazawa Univ | 血管形成促進剤 |
| US20110097710A1 (en) | 2004-10-26 | 2011-04-28 | Macrae Calum A | Methods for detecting atrial fibrillation and related conditions |
| WO2006076736A2 (en) | 2005-01-14 | 2006-07-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
| US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
| US20080031871A1 (en) | 2006-02-21 | 2008-02-07 | Allen Margaret L | Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene |
| US20090324610A1 (en) | 2006-04-25 | 2009-12-31 | Kyushu Univeristy, National University Corporation | Gene associated with arteriosclerotic disease, and use thereof |
| US20100286029A1 (en) | 2007-09-11 | 2010-11-11 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| WO2009033819A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US20110123534A1 (en) | 2007-12-12 | 2011-05-26 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
| WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| RU2011122482A (ru) | 2008-11-04 | 2012-12-20 | Энкер Терапьютикс, Инк. | Apj-рецепторы соединения |
| WO2010115874A1 (en) | 2009-04-07 | 2010-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the diagnosis ofpulmonary arterial hypertension |
| JP2013509874A (ja) | 2009-11-04 | 2013-03-21 | エラスムス ユニバーシティ メディカル センター ロッテルダム | 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法 |
| CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| RU2457216C1 (ru) | 2010-12-21 | 2012-07-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | Додекапептиды, обладающие кардиопротекторными свойствами |
| CN104254540A (zh) | 2012-01-09 | 2014-12-31 | 安科治疗公司 | Apj受体化合物 |
| EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
| EP3024847A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Disulfide cyclic polypeptides for the treatment of heart failure |
| WO2015013165A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic apelin derivatives for the treatment of heart failure |
| WO2015013169A2 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
-
2013
- 2013-01-23 US US13/747,621 patent/US8673848B2/en not_active Expired - Fee Related
- 2013-01-24 JO JOP/2013/0027A patent/JO3380B1/ar active
- 2013-01-24 UY UY0001034593A patent/UY34593A/es not_active Application Discontinuation
- 2013-01-25 TW TW102103025A patent/TWI576356B/zh not_active IP Right Cessation
- 2013-01-25 MY MYPI2014002154A patent/MY172268A/en unknown
- 2013-01-25 HU HUE13711953A patent/HUE039137T2/hu unknown
- 2013-01-25 PT PT137119533T patent/PT2807183T/pt unknown
- 2013-01-25 DK DK13711953.3T patent/DK2807183T3/en active
- 2013-01-25 JP JP2014553847A patent/JP6313222B2/ja not_active Expired - Fee Related
- 2013-01-25 CN CN201380016261.6A patent/CN104220452B/zh not_active Expired - Fee Related
- 2013-01-25 WO PCT/IB2013/050666 patent/WO2013111110A2/en not_active Ceased
- 2013-01-25 RS RS20180546A patent/RS57200B1/sr unknown
- 2013-01-25 SI SI201330999T patent/SI2807183T1/en unknown
- 2013-01-25 CA CA2862240A patent/CA2862240A1/en active Pending
- 2013-01-25 KR KR1020197037887A patent/KR20200003229A/ko not_active Ceased
- 2013-01-25 SG SG11201404369PA patent/SG11201404369PA/en unknown
- 2013-01-25 AR ARP130100228A patent/AR089808A1/es unknown
- 2013-01-25 HR HRP20180806TT patent/HRP20180806T1/hr unknown
- 2013-01-25 BR BR112014018306A patent/BR112014018306A8/pt not_active IP Right Cessation
- 2013-01-25 AU AU2013213265A patent/AU2013213265C1/en not_active Ceased
- 2013-01-25 CU CUP2014000097A patent/CU24266B1/xx unknown
- 2013-01-25 PL PL13711953T patent/PL2807183T3/pl unknown
- 2013-01-25 EP EP13711953.3A patent/EP2807183B1/en active Active
- 2013-01-25 KR KR1020147023505A patent/KR102068370B1/ko not_active Expired - Fee Related
- 2013-01-25 TR TR2018/07309T patent/TR201807309T4/tr unknown
- 2013-01-25 UA UAA201408328A patent/UA116196C2/uk unknown
- 2013-01-25 PE PE2014001176A patent/PE20142194A1/es active IP Right Grant
- 2013-01-25 EA EA201491433A patent/EA027853B1/ru not_active IP Right Cessation
- 2013-01-25 LT LTEP13711953.3T patent/LT2807183T/lt unknown
- 2013-01-25 NZ NZ627772A patent/NZ627772A/en not_active IP Right Cessation
- 2013-01-25 AP AP2014007846A patent/AP2014007846A0/xx unknown
- 2013-01-25 ES ES13711953.3T patent/ES2670832T3/es active Active
- 2013-01-25 MX MX2014009085A patent/MX351569B/es active IP Right Grant
-
2014
- 2014-01-28 US US14/165,680 patent/US9067971B2/en active Active
- 2014-07-22 ZA ZA2014/05400A patent/ZA201405400B/en unknown
- 2014-07-23 TN TNP2014000318A patent/TN2014000318A1/fr unknown
- 2014-07-24 IL IL233792A patent/IL233792B/en active IP Right Grant
- 2014-07-25 CL CL2014001994A patent/CL2014001994A1/es unknown
- 2014-07-25 GT GT201400166A patent/GT201400166A/es unknown
- 2014-07-25 PH PH12014501701A patent/PH12014501701A1/en unknown
- 2014-07-28 CR CR20140364A patent/CR20140364A/es unknown
- 2014-07-31 CO CO14167109A patent/CO7020879A2/es unknown
- 2014-08-27 EC ECIEPI201416014A patent/ECSP14016014A/es unknown
-
2015
- 2015-05-18 US US14/714,914 patent/US9982017B2/en not_active Expired - Fee Related
-
2017
- 2017-10-06 JP JP2017195815A patent/JP6595553B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-24 CY CY20181100556T patent/CY1120239T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233792B (en) | A synthetic apelin mimetic polypeptide for the treatment of heart failure | |
| SG11201405530SA (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| GB201218307D0 (en) | Patient monitor | |
| IL263661A (en) | Combination therapy for the treatment of glioblastoma | |
| GB201321559D0 (en) | Diagnosis of the condition of apparatus | |
| ZA201500229B (en) | Combinations of modalities for the treatment of diabetes | |
| IL243682A0 (en) | Cyclic polypeptides for the treatment of heart failure | |
| GB201219873D0 (en) | Diverticulitis treatment | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| GB201217439D0 (en) | Combination therapy | |
| GB2508667B (en) | Diagnosis of the condition of apparatus | |
| GB201207305D0 (en) | Therapy | |
| IL238174A0 (en) | Combined treatment with Valasertiv | |
| SMT201900108T1 (it) | Diagnosi di insufficienza cardiaca | |
| SI2855487T1 (sl) | Spojine za zdravljenje ishemično-reperfuzijsko-povezanih bolezni | |
| GB201215502D0 (en) | Medical use | |
| AP2015008270A0 (en) | Preparation for the treatment of tuberculosis | |
| GB201207363D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201207359D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201211543D0 (en) | Combination therapy | |
| GB201219207D0 (en) | Non-invasive monitor | |
| GB201215621D0 (en) | Medical solution | |
| GB201216381D0 (en) | New compounds and medical uses | |
| GB201208970D0 (en) | New compounds and medical uses |